Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy

Improved Basophil Activation Test (BAT) in the Diagnostics of IgE-mediated Drug Allergy

Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs).

Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). Among commonly used CD63/CD203c markers, newly proposed molecules, such as CD69, CD107a, CD164, CD13, CD11b and CD300a will be assayed. Results obtained together with the other clinical data will be used to calculate sensitivity and specificity of the method.

Inclusion Criteria:

• suspected allergy to antibiotics or NSAIDs in the last 1 year.

Exclusion Criteria:

• autoimmune diseases;
• HIV;
• hepatitis B/C;
• other acute or chronic infectious diseases;
• malignant neoplasms;
• leukemia;
• other severe acute or chronic intercurrent diseases;
• pregnancy/lactation;
• refuse of patient to participate in the trial.